Spebrutinib besylate
Based on 17 publication(s) in Google Scholar
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
For research use only. We do not sell to patients.
- CAS No.: 1360053-81-1
- Formula: C28H28FN5O6S
- Molecular Weight:581.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Spebrutinib besylate
More- Blood. 2016 Jun 23;127(25):3237-52. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Br J Pharmacol. 2019 Dec;176(23):4491-4509. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Stem Cell Reports. 2019 May 14;12(5):996-1006. [Abstract]
- Molecules. 2022 Dec 22;28(1):79. [Abstract]
- Sci Rep. 2026 Mar 20;16(1):14300. [Abstract]
- iScience. 2024 Sep 24;27(11):110961. [Abstract]
- ACS Pharmacol Transl Sci. 2025 Mar 12;8(4):917-931. [Abstract]
- R Soc Open Sci. 2019 Jun 5;6(6):190434. [Abstract]
- Leuk Res. 2020 Jan:88:106286. [Abstract]
- bioRxiv. 2025 Jun 22:2025.06.19.660637. [Abstract]
- bioRxiv. 2024 September 08.
- Heliyon. 2023 Jun 9;9(6):e17058. [Abstract]
- Methods Mol Biol. 2018:1711:351-398. [Abstract]
- Oncotarget. 2017 Nov 30;8(67):111386-111395. [Abstract]
- Patent. US20170333436A1.
Biological Activity
Description
IC50 & Target
IC50: <0.5 nM (Btk)[1]
In Vitro
Spebrutinib (CC-292) is a covalent, highly selective, orally active inhibitor of Btk with IC50 value of 0.5 nM. Spebrutinib also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC50s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, rspectively. Extensive analysis has revealed that the EC50 of Btk occupancy from a Spebrutinib dose-response in Ramos cells (EC50=6 nM) correlated directly with the cellular EC50 of Btk kinase inhibition with Spebrutinib (EC50=8 nM). Furthermore, the concentration at which Spebrutinib inhibits 90% of Btk activity in Ramos cells is 35 nM while the concentration of Spebrutinib required for 90% occupancy of Btk is 39 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1360053-81-1
-
Molecular Weight 581.62
-
Formula C28H28FN5O6S
-
SMILES
COCCOC1=CC=C(NC2=NC=C(F)C(NC3=CC=CC(NC(C=C)=O)=C3)=N2)C=C1.O=S(C4=CC=CC=C4)(O)=O
-
Synonyms
AVL-292 benzenesulfonate; CC-292 besylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Blood
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. [Abstract]2016 Jun 23;127(25):3237-52. PMID: 27143257 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Br J Pharmacol
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. [Abstract]2019 Dec;176(23):4491-4509. PMID: 31364164 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Stem Cell Reports
2019 May 14;12(5):996-1006. PMID: 31031187 -
Molecules
A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma-Application to a Pharmacokinetic Study. [Abstract]2022 Dec 22;28(1):79. PMID: 36615272 -
Sci Rep
2026 Mar 20;16(1):14300. PMID: 41862552 -
iScience
Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746. [Abstract]2024 Sep 24;27(11):110961. PMID: 39759071 -
ACS Pharmacol Transl Sci
Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures. [Abstract]2025 Mar 12;8(4):917-931. PMID: 40242575 -
R Soc Open Sci
A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. [Abstract]2019 Jun 5;6(6):190434. PMID: 31312501 -
Leuk Res
Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. [Abstract]2020 Jan:88:106286. PMID: 31865062 -
bioRxiv
2025 Jun 22:2025.06.19.660637. PMID: 40666940 -
-
Heliyon
Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study. [Abstract]2023 Jun 9;9(6):e17058. PMID: 37484253 -
Methods Mol Biol
2018:1711:351-398. PMID: 29344898 -
Oncotarget
Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. [Abstract]2017 Nov 30;8(67):111386-111395. PMID: 29340061 -
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)